Study identifier:H8O-JE-GWBB
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Efficacy and Safety of LY2148568 in Japanese Patients with Type 2 Diabetes Who are Treated with Oral Antidiabetic(s) but not well Controlled
Type 2 Diabetes
Phase 3
No
exenatide, placebo
All
181
Interventional
20 Years - 75 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Eli Lilly and Company
This long term, placebo-controlled trial is intended to assess the efficacy and safety of exenatide, dosed twice a day, in Japanese patients with Type 2 Diabetes who are treated with oral antidiabetic(s) but not well controlled.
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: exenatide subcutaneous injection, 5mcg, twice a day Other Name: LY2148568 Other Name: Byetta |
Experimental: 2 | Drug: exenatide subcutaneous injection, 10mcg, twice a day Other Name: LY2148568 Other Name: Byetta |
Placebo Comparator: 3 | Drug: placebo subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.